Olema Oncology

Olema Oncology

Biotechnology Research

San Francisco, California 8,152 followers

About us

Olema Oncology is a cancer medicines company dedicated to impacting breast cancer and beyond. Our lead program, palazestrant (OP-1250), is a differentiated oral medicine known as a complete estrogen receptor antagonist (CERAN) initially in development for metastatic breast cancer. Our pipeline also includes OP-3136, a potent, selective oral inhibitor of the KAT6 pathway. At Olema, we are building a focused team committed to our mission with intention and clarity. Working alongside a talented, passionate group of leaders and advisors, we strive to create better medicines that aim to help patients feel better, longer. For more information, visit us at www.olema.com.

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
San Francisco, California
Type
Public Company
Founded
2007
Specialties
pharmaceuticals, biotechnology, drug development, oncology, breast cancer, nuclear receptors, and small molecules

Locations

Employees at Olema Oncology

Updates

Similar pages

Browse jobs